Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin

TY - JOUR

T1 - Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin

AU - Schmalbrock, Laura Katharina

AU - Dolnik, Anna

AU - Cocciardi, Sibylle

AU - Sträng, Eric

AU - Theis, Frauke

AU - Jahn, Nikolaus

AU - Panina, Ekaterina

AU - Blätte, Tamara Jacqueline

AU - Herzig, Julia K

AU - Skambraks, Sabrina

AU - Rücker, Frank G

AU - Gaidzik, Verena I

AU - Paschka, Peter

AU - Fiedler, Walter

AU - Salih, Helmut Rainer

AU - Wulf, Gerald G

AU - Schroeder, Thomas

AU - Lübbert, Michael

AU - Schlenk, Richard F

AU - Thol, Felicitas

AU - Heuser, Michael

AU - Larson, Richard A

AU - Ganser, Arnold

AU - Stunnenberg, Hendrik G

AU - Minucci, Saverio

AU - Stone, Richard M

AU - Bloomfield, Clara D

AU - Döhner, Hartmut

AU - Döhner, Konstanze

AU - Bullinger, Lars

N1 - © 2021 by The American Society of Hematology.

PY - 2021/6/3

Y1 - 2021/6/3

N2 - In the international randomized phase 3 RATIFY (Randomized AML Trial In FLT3 in patients less than 60 Years old) trial, the multikinase inhibitor midostaurin significantly improved overall and event-free survival in patients 18 to 59 years of age with FLT3-mutated acute myeloid leukemia (AML). However, only 59% of patients in the midostaurin arm achieved protocol-specified complete remission (CR), and almost half of patients achieving CR relapsed. To explore underlying mechanisms of resistance, we studied patterns of clonal evolution in patients with FLT3-internal tandem duplications (ITD)-positive AML who were entered in the RATIFY or German-Austrian Acute Myeloid Leukemia Study Group 16-10 trial and received treatment with midostaurin. To this end, paired samples from 54 patients obtained at time of diagnosis and at time of either relapsed or refractory disease were analyzed using conventional Genescan-based testing for FLT3-ITD and whole exome sequencing. At the time of disease resistance or progression, almost half of the patients (46%) became FLT3-ITD negative but acquired mutations in signaling pathways (eg, MAPK), thereby providing a new proliferative advantage. In cases with FLT3-ITD persistence, the selection of resistant ITD clones was found in 11% as potential drivers of disease. In 32% of cases, no FLT3-ITD mutational change was observed, suggesting either resistance mechanisms bypassing FLT3 inhibition or loss of midostaurin inhibitory activity because of inadequate drug levels. In summary, our study provides novel insights into the clonal evolution and resistance mechanisms of FLT3-ITD-mutated AML under treatment with midostaurin in combination with intensive chemotherapy.

AB - In the international randomized phase 3 RATIFY (Randomized AML Trial In FLT3 in patients less than 60 Years old) trial, the multikinase inhibitor midostaurin significantly improved overall and event-free survival in patients 18 to 59 years of age with FLT3-mutated acute myeloid leukemia (AML). However, only 59% of patients in the midostaurin arm achieved protocol-specified complete remission (CR), and almost half of patients achieving CR relapsed. To explore underlying mechanisms of resistance, we studied patterns of clonal evolution in patients with FLT3-internal tandem duplications (ITD)-positive AML who were entered in the RATIFY or German-Austrian Acute Myeloid Leukemia Study Group 16-10 trial and received treatment with midostaurin. To this end, paired samples from 54 patients obtained at time of diagnosis and at time of either relapsed or refractory disease were analyzed using conventional Genescan-based testing for FLT3-ITD and whole exome sequencing. At the time of disease resistance or progression, almost half of the patients (46%) became FLT3-ITD negative but acquired mutations in signaling pathways (eg, MAPK), thereby providing a new proliferative advantage. In cases with FLT3-ITD persistence, the selection of resistant ITD clones was found in 11% as potential drivers of disease. In 32% of cases, no FLT3-ITD mutational change was observed, suggesting either resistance mechanisms bypassing FLT3 inhibition or loss of midostaurin inhibitory activity because of inadequate drug levels. In summary, our study provides novel insights into the clonal evolution and resistance mechanisms of FLT3-ITD-mutated AML under treatment with midostaurin in combination with intensive chemotherapy.

U2 - 10.1182/blood.2020007626

DO - 10.1182/blood.2020007626

M3 - SCORING: Journal article

C2 - 33598693

VL - 137

SP - 3093

EP - 3104

JO - BLOOD

JF - BLOOD

SN - 0006-4971

IS - 22

ER -